Company Filing History:
Years Active: 2005
Title: Chiharu Masuyama: Innovator in Bone-Pathobolism Treatment
Introduction
Chiharu Masuyama is a prominent inventor based in Ishibashi-machi, Japan. She has made significant contributions to the field of medicine, particularly in the treatment of bone-pathobolism. Her innovative work has led to the development of a novel therapeutic agent that addresses critical health issues.
Latest Patents
Masuyama holds a patent for a bone-pathobolism treating agent. This agent comprises at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), its homologs, and its variants, along with a polysaccharide or its derivatives. The polysaccharides, such as heparin and dextran sulfate, are utilized for their excellent therapeutic effects on conditions like osteoporosis, hypercalcemia, and chronic articular rheumatism. This agent is recognized for its persistence of activity and usefulness as a medicine.
Career Highlights
Chiharu Masuyama is associated with Sankyo Company, Limited, where she continues to advance her research and development efforts. Her work has garnered attention for its potential to improve the quality of life for individuals suffering from bone-related diseases.
Collaborations
Masuyama has collaborated with notable colleagues, including Shinichi Mochizuki and Nobuaki Fujise. These partnerships have contributed to her innovative research and the successful development of her patent.
Conclusion
Chiharu Masuyama is a trailblazer in the field of bone-pathobolism treatment, with her patented agent offering hope for effective medical solutions. Her contributions to the medical field highlight the importance of innovation in addressing health challenges.